1. Indications and Usage
\nGastrointestinal Stromal Tumor (GIST): Treatment of patients with imatinib-resistant or -intolerant GIST .
\nAdvanced Renal Cell Carcinoma (RCC): Treatment of patients with advanced RCC .
\nPancreatic Neuroendocrine Tumors (pNET): Treatment of adult patients with progressive, non-functioning pNET .
\n2. Dosage and Administration
\nAdministration: Oral administration. Capsules must be swallowed whole with water. Can be taken with or without food .
\nStandard Dose:
\nGIST and RCC: 50 mg once daily for 4 weeks, followed by a 2-week rest period (Schedule 4\/2) .
\npNET: 37.5 mg once daily, continuously (no rest period) .
\nDose Adjustment: Dose reductions (e.g., to 37.5 mg or 25 mg) or increases may be recommended based on individual safety and tolerability. Adjustments are also required when co-administered with CYP3A4 inhibitors or inducers .
\n3. Mechanism of Action
\nSunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor.
\nIt inhibits multiple RTKs involved in tumor growth, pathologic angiogenesis, and metastatic progression, including PDGFR, VEGFR, KIT, FLT3, CSF-1R, and RET .
\nBy blocking these receptors, it “starves” the tumor of blood supply and inhibits tumor cell proliferation.
\n4. Safety and Warnings
\nCardiac Dysfunction: Can cause left ventricular dysfunction and heart failure. Monitor LVEF prior to and during treatment .
\nHypertension: Monitoring of blood pressure is recommended during treatment .
\nHepatotoxicity: Monitor liver function tests (ALT, AST, bilirubin) regularly .
\nQTc Interval Prolongation: Monitor ECG and electrolytes periodically, especially in patients with cardiac history .
\nThyroid Dysfunction: Monitor thyroid function tests periodically, as hypothyroidism is common .
\nHemorrhage and Adrenal Insufficiency: Monitor for signs of bleeding and adrenal insufficiency .
\n5. Adverse Reactions
\nCommon adverse reactions (incidence \u226510%) include:
\nGeneral: Fatigue, asthenia, pyrexia.
\nGastrointestinal: Diarrhea, nausea, stomatitis, vomiting, dyspepsia, constipation, abdominal pain, altered taste.
\nSkin: Skin discoloration (yellowing), rash, hand-foot syndrome .
\nCardiovascular: Hypertension.
\nLaboratory Abnormalities: Neutropenia, thrombocytopenia, anemia, increased lipase, increased creatinine .
\n6. Drug Interactions
\nCYP3A4 Inhibitors: Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) increases Sunitinib exposure. Dose reduction is required .
\nCYP3A4 Inducers: Concomitant use with strong CYP3A4 inducers (e.g., rifampin) decreases Sunitinib exposure. Dose increase may be required .
\nGrapefruit Juice: Avoid consumption of grapefruit or grapefruit juice as it may increase drug exposure .
\n7. Pharmaceutical Information
\nChemical Name: Indoline-5-carboxamide, N-(2-(diethylamino)ethyl)-2-oxo-1-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)-, (indol-5-yl)acetate (1:1) .
\nMolecular Formula: C22H27FN4O2 \u00b7 C4H6O5 .
\nStorage: Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) .<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u7d22\u5766 \u00ae(Sutent\u00ae)
\nGeneric Name: Sunitinib Malate
\nStrength: 12.5 mg per capsule, 28 capsules per bottle
\nManufacturer: Pfizer Italia S.r.l.
\nMarketing Authorization Holder: PFIZER EUROPE MA EEIG\uff1b\u5883\u5185\u8d23\u4efb\u4eba\uff1a\u8f89\u745e\u6295\u8d44\u6709\u9650\u516c\u53f8
\nApproval Date in China: Original approval in 2009, updated registration in 2017
\nRegistration Number: \u56fd\u836f\u51c6\u5b57HJ20171137
\nStorage: Store at 25\u2103, short-term transportation between 15\u2103\u201330\u2103 is permitted; seal tightly, protect from light and moisture, keep away from children<\/p>\n
Price&Cost:Contact Us now for the best price of Sunitinib Malate\uff08Sutent\uff09<\/p>\n","protected":false},"featured_media":2878,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[81],"product_cat":[26],"product_tag":[],"class_list":["post-2877","product","type-product","status-publish","has-post-thumbnail","product_brand-pfizer","product_cat-capsules","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n